PortfoliosLab logo
CPRX vs. XPEL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CPRX and XPEL is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

CPRX vs. XPEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL). The values are adjusted to include any dividend payments, if applicable.

500.00%1,000.00%1,500.00%2,000.00%NovemberDecember2025FebruaryMarchApril
547.79%
1,272.50%
CPRX
XPEL

Key characteristics

Sharpe Ratio

CPRX:

1.43

XPEL:

-0.64

Sortino Ratio

CPRX:

2.29

XPEL:

-0.74

Omega Ratio

CPRX:

1.26

XPEL:

0.88

Calmar Ratio

CPRX:

1.96

XPEL:

-0.66

Martin Ratio

CPRX:

8.26

XPEL:

-1.54

Ulcer Index

CPRX:

7.17%

XPEL:

32.20%

Daily Std Dev

CPRX:

41.42%

XPEL:

77.40%

Max Drawdown

CPRX:

-94.25%

XPEL:

-99.77%

Current Drawdown

CPRX:

-8.90%

XPEL:

-72.93%

Fundamentals

Market Cap

CPRX:

$2.83B

XPEL:

$757.67M

EPS

CPRX:

$1.31

XPEL:

$1.65

PE Ratio

CPRX:

17.70

XPEL:

16.61

PS Ratio

CPRX:

5.75

XPEL:

1.80

PB Ratio

CPRX:

3.88

XPEL:

3.36

Total Revenue (TTM)

CPRX:

$393.23M

XPEL:

$330.30M

Gross Profit (TTM)

CPRX:

$327.56M

XPEL:

$139.48M

EBITDA (TTM)

CPRX:

$177.46M

XPEL:

$57.76M

Returns By Period

In the year-to-date period, CPRX achieves a 12.36% return, which is significantly higher than XPEL's -31.27% return. Over the past 10 years, CPRX has underperformed XPEL with an annualized return of 20.83%, while XPEL has yielded a comparatively higher 27.01% annualized return.


CPRX

YTD

12.36%

1M

-6.76%

6M

9.27%

1Y

59.74%

5Y*

36.21%

10Y*

20.83%

XPEL

YTD

-31.27%

1M

-17.84%

6M

-30.40%

1Y

-48.95%

5Y*

20.30%

10Y*

27.01%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CPRX vs. XPEL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
The Risk-Adjusted Performance Rank of CPRX is 9090
Overall Rank
The Sharpe Ratio Rank of CPRX is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 8989
Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 8585
Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 9393
Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 9393
Martin Ratio Rank

XPEL
The Risk-Adjusted Performance Rank of XPEL is 1414
Overall Rank
The Sharpe Ratio Rank of XPEL is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of XPEL is 1818
Sortino Ratio Rank
The Omega Ratio Rank of XPEL is 1515
Omega Ratio Rank
The Calmar Ratio Rank of XPEL is 1111
Calmar Ratio Rank
The Martin Ratio Rank of XPEL is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CPRX vs. XPEL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for CPRX, currently valued at 1.43, compared to the broader market-2.00-1.000.001.002.003.00
CPRX: 1.43
XPEL: -0.64
The chart of Sortino ratio for CPRX, currently valued at 2.29, compared to the broader market-6.00-4.00-2.000.002.004.00
CPRX: 2.29
XPEL: -0.74
The chart of Omega ratio for CPRX, currently valued at 1.26, compared to the broader market0.501.001.502.00
CPRX: 1.26
XPEL: 0.88
The chart of Calmar ratio for CPRX, currently valued at 1.96, compared to the broader market0.001.002.003.004.005.00
CPRX: 1.96
XPEL: -0.66
The chart of Martin ratio for CPRX, currently valued at 8.26, compared to the broader market-5.000.005.0010.0015.0020.00
CPRX: 8.26
XPEL: -1.54

The current CPRX Sharpe Ratio is 1.43, which is higher than the XPEL Sharpe Ratio of -0.64. The chart below compares the historical Sharpe Ratios of CPRX and XPEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
1.43
-0.64
CPRX
XPEL

Dividends

CPRX vs. XPEL - Dividend Comparison

Neither CPRX nor XPEL has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CPRX vs. XPEL - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, smaller than the maximum XPEL drawdown of -99.77%. Use the drawdown chart below to compare losses from any high point for CPRX and XPEL. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2025FebruaryMarchApril
-8.90%
-72.93%
CPRX
XPEL

Volatility

CPRX vs. XPEL - Volatility Comparison

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 14.53%, while XPEL, Inc. (XPEL) has a volatility of 20.72%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than XPEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%NovemberDecember2025FebruaryMarchApril
14.53%
20.72%
CPRX
XPEL

Financials

CPRX vs. XPEL - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and XPEL, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items